Metabolite profiling of 14C-omacetaxine mepesuccinate in plasma and excreta of cancer patients-Reference-Cited by-同舟云学术

Metabolite profiling of 14C-omacetaxine mepesuccinate in plasma and excreta of cancer patients

Published:2016-03-21 Issue:12 Volume:46 Page:1122-1132
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Nijenhuis Cynthia M.¹,Lucas Luc¹,Rosing Hilde¹,Robertson Philmore²,Hellriegel Edward T.²,Schellens Jan H. M.³⁴,Beijnen and Jos H.¹⁴

Affiliation:

1. Department of Pharmacy and Pharmacology, Antoni Van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands,

2. Nonclinical DMPK, Teva Branded Pharmaceutical R&D, Inc., West Chester, PA, USA,

3. Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands and

4. Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3109/00498254.2016.1152418

Reference21 articles.

1. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

2. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

3. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

4. Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

5. The molecular biology of chronic myeloid leukemia

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA-cloaked nanoparticles for tumor microenvironment-responsive activation;Journal of Controlled Release;2022-10

2. Natural Products as Cytotoxic Agents;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26

3. Biodiversity, chemodiversity, and pharmacotherapy of Cephalotaxus medicinal plants;Taxaceae and Cephalotaxaceae;2021

4. Separation and characterization of forced degradation products in homoharringtonine injection by UHPLC-Q-TOF-MS;Journal of Pharmaceutical and Biomedical Analysis;2019-11

5. MetaQSAR: An Integrated Database Engine to Manage and Analyze Metabolic Data;Journal of Medicinal Chemistry;2018-01-17